Fred Alger Management LLC Lowers Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Fred Alger Management LLC decreased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 20.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,211 shares of the biotechnology company’s stock after selling 1,334 shares during the quarter. Fred Alger Management LLC’s holdings in ADMA Biologics were worth $104,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. USA Financial Formulas raised its holdings in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares during the period. Vontobel Holding Ltd. increased its stake in ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 888 shares during the period. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics during the third quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 1,509 shares during the period. Finally, Larson Financial Group LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at approximately $31,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several recent research reports. HC Wainwright raised their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $20.11 on Monday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $19.08 and a 200-day simple moving average of $15.40. The stock has a market cap of $4.75 billion, a P/E ratio of 71.82 and a beta of 0.64. ADMA Biologics, Inc. has a 12-month low of $3.60 and a 12-month high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same period in the previous year, the business earned $0.01 EPS. Equities analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This trade represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.